{
  "input": {
    "mode": "build_counterchain",
    "query": {
      "entity": "Atypical haemolytic uraemic syndrome",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_ravulizumab",
          "name": "Ravulizumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_avacopan",
          "name": "Avacopan"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_complement_c5_inhibitors",
          "name": "Complement C5 Inhibitors"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_cangrelor",
          "name": "Cangrelor"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_nivolumab",
          "name": "Nivolumab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_eculizumab_biosimilar",
          "name": "Eculizumab Biosimilar"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_tafamidis",
          "name": "Tafamidis"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_ertugliflozin",
          "name": "Ertugliflozin"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_daratumumab",
          "name": "Daratumumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_obinutuzumab",
          "name": "Obinutuzumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_caplacizumab",
          "name": "Caplacizumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 3
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "n_ot_eculizumab",
          "type": "Target",
          "label": "OffTarget_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_eculizumab",
          "type": "Pathway",
          "label": "RiskPathway_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_eculizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_ravulizumab",
          "type": "Target",
          "label": "OffTarget_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_ravulizumab",
          "type": "Pathway",
          "label": "RiskPathway_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_ravulizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_avacopan",
          "type": "Target",
          "label": "OffTarget_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_avacopan",
          "type": "Pathway",
          "label": "RiskPathway_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_avacopan",
          "type": "Phenotype",
          "label": "AdversePhenotype_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_c5_inhibitors",
          "type": "Target",
          "label": "OffTarget_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_c5_inhibitors",
          "type": "Pathway",
          "label": "RiskPathway_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_c5_inhibitors",
          "type": "Phenotype",
          "label": "AdversePhenotype_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_eculizumab",
          "target": "n_ot_eculizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_eculizumab",
          "target": "n_rp_eculizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_eculizumab",
          "target": "n_adv_eculizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_eculizumab",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_ravulizumab",
          "target": "n_ot_ravulizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_ravulizumab",
          "target": "n_rp_ravulizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_ravulizumab",
          "target": "n_adv_ravulizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_ravulizumab",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_avacopan",
          "target": "n_ot_avacopan",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_avacopan",
          "target": "n_rp_avacopan",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_avacopan",
          "target": "n_adv_avacopan",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_avacopan",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_complement_c5_inhibitors",
          "target": "n_ot_c5_inhibitors",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_c5_inhibitors",
          "target": "n_rp_c5_inhibitors",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_c5_inhibitors",
          "target": "n_adv_c5_inhibitors",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_c5_inhibitors",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        }
      ],
      "conflict_hotspots": [
        {
          "topic": "risk_of_adverse_effects",
          "pro_nodes": [
            "n_rp_eculizumab",
            "n_rp_ravulizumab",
            "n_rp_avacopan",
            "n_rp_c5_inhibitors"
          ],
          "con_nodes": [
            "n_adv_eculizumab",
            "n_adv_ravulizumab",
            "n_adv_avacopan",
            "n_adv_c5_inhibitors"
          ],
          "note": "不同药物可能引发不良反应的风险"
        }
      ]
    },
    "counterclaims": [
      {
        "id": "K1",
        "text": "潜在的非靶向效果可能显著影响患者安全性",
        "confidence": "high"
      },
      {
        "id": "K2",
        "text": "长期使用可能导致耐受，不良反应风险增加",
        "confidence": "medium"
      }
    ],
    "assumptions_challenged": [
      "各药物在靶器官的疗效和安全性是否完全评估",
      "短期效果是否可以推广至长期使用"
    ],
    "falsification_tests": [
      "是否存在任何数据表明这些药物在长期使用中的安全性",
      "是否有临床研究表明靶点外作用的潜在影响"
    ],
    "next_focus_for_pi": [
      "确认各药物不良反应的具体机制",
      "对冲突热点进行更深入的研究"
    ]
  }
}